Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals

Area of Science:

• Endocrinology
• Pharmacology
• Rheumatology

Background:

• Hydroxychloroquine (HCQ) is a disease-modifying therapy for rheumatoid arthritis (RA).
• Previous studies suggest HCQ may reduce diabetes mellitus risk in RA patients.
• The mechanism for this potential benefit is not fully understood.

Purpose of the Study:

• To investigate the effects of HCQ on insulin resistance, insulin sensitivity, and pancreatic beta-cell function.
• To explore the potential of HCQ as an insulin sensitizer.

Main Methods:

• An open-label, longitudinal study involving 13 obese, non-diabetic subjects.
• HCQ administered at 6.5 mg/kg/day for six weeks.
• Oral glucose tolerance tests and calculations of Matsuda Insulin Sensitivity Index (ISI), HOMA-IR, and HOMA-B at baseline, 6 weeks, and 12 weeks.

Main Results:

• After 6 weeks of HCQ, ISI significantly increased (p=0.040).
• HOMA-IR showed a trend toward reduction (p=0.09).
• These metabolic improvements returned to baseline by 12 weeks post-treatment.

Conclusions:

• Six weeks of HCQ treatment improved insulin sensitization in obese, non-diabetic subjects.
• HCQ demonstrates potential insulin-sensitizing properties.
• Further research is warranted to explore HCQ's effects on insulin sensitization in RA patients.